Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · May 25, 2015

Survival in ALK-Positive NSCLC With Sequential Crizotinib and Ceritinib

Clinical Cancer Research

 

Additional Info

Clinical Cancer Research
Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated With Sequential Crizotinib and Ceritinib
Clin. Cancer Res 2015 May 12;[EPub Ahead of Print], JF Gainor, DS Tan, T De Pas, BJ Solomon, A Ahmad, C Lazzari, F de Marinis, G Spitaleri, K Schultz, L Friboulet, BY Yeap, JA Engelman, AT Shaw

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading